• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
 

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Options
  • Details
BORIS DOI
10.7892/boris.92056
Date of Publication
September 20, 2016
Publication Type
Article
Division/Institute

Institut für Patholog...

Contributor
Galon, J
Fox, B A
Bifulco, C B
Masucci, G
Rau, Tilmanorcid-logo
Institut für Pathologie, Klinische Pathologie
Botti, G
Marincola, F M
Ciliberto, G
Pages, F
Ascierto, P A
Capone, M
Series
Journal of translational medicine
ISSN or ISBN (if monograph)
1479-5876
Publisher
BioMed Central
Language
English
Publisher DOI
10.1186/s12967-016-1029-z
PubMed ID
27650038
Uncontrolled Keywords

Immunoprofiling

Immunoscore

Melanoma

Description
The fifth "Melanoma Bridge Meeting" took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/147428
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
immunoscore.pdftextAdobe PDF822.83 KBAttribution (CC BY 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 960e9e [21.08. 13:49]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo